Start-up raises $173 million to develop gene-therapy-alternative infusion for sickle cell disease

A new biotechnology company has secured substantial funding to pursue a sickle cell treatment designed to match gene therapy efficacy without the manufacturing and delivery complexities associated with current gene-based approaches.

Published · AI-drafted summary based on 1 public source
Illustration for rare disease story
Illustrative image — not from the source article.
Share

STAT News reports that a new start-up has raised $173 million to develop an infusion-based treatment for sickle cell disease that its founders say could achieve outcomes comparable to gene therapy, without the drawbacks — including the high cost, lengthy manufacturing time, and conditioning regimens currently required for gene therapy approaches.

Sickle cell disease affects millions of people worldwide and is caused by a well-characterised mutation in the β-globin gene. While gene therapies for SCD have received regulatory approval in recent years, their real-world uptake has been limited by logistical and cost barriers. The start-up's approach, described in STAT News but not yet in peer-reviewed literature, is positioned as a simpler alternative delivery modality.

The report does not provide detailed mechanistic information about the treatment or preclinical data. As a funding announcement, it reflects investor and founder confidence in a research hypothesis rather than documented clinical efficacy. Researchers and those tracking the sickle cell therapeutic landscape may note it as a signal of continued interest in non-gene-therapy modalities for haemoglobinopathies.

Sources

Read the original reporting — these are the public sources this summary draws from.

  1. Primary source Stat News · 2026-11-17
    STAT+: With $173 million, new startup takes aim at sickle cell

Tags

sickle-cell-disease drug-development biotech haemoglobinopathy investment rare-disease
Share

About Genetic Current

Educational summaries of public genetics news

Genetic Current is the news section of Evagene, an academic, research, and educational pedigree-modelling platform. Stories are AI-drafted summaries of items from trusted public sources, written for researchers, clinicians, educators, students, genealogists, and patients with an interest in genetics. Summaries are for educational and research purposes only and are not medical advice.

Join the Evagene Alpha Waiting List